Navigation Links
Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
Date:10/11/2011

p>Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about EXPAREL's potential, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the timing of, and our ability to obtain regulatory approval of EXPAREL; the timing of our anticipated commercial launch of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and our ability to serve those markets; our commercialization and marketing capabilities; and other factors discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2010, and in other filings that we periodically make with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Contacts:

James S. Scibetta
Chief Financial Officer
Pacira Pharmaceuticals, Inc.
(973) 254-3570

Dan Budwick
Vice President, Media Relations
Pure Communications, Inc.
(973) 271-6085


'/>"/>
SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
5. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
6. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
7. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
8. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
9. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
10. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
11. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
(Date:1/22/2015)... Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... on advanced wound care, announces that AMNIOEXCEL® and ... been added to the Premier, Inc. Regenerative Skin ... for the AMNIOEXCEL® and AMNIOMATRIX® product lines, which ...
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... NanoLogix, Inc. (OTC:,NNLX - News) a nano-biotechnology ... company events:, NanoLogix personnel are manning a ... in Sacramento this week, with the company being,represented ... will be,presenting in the Exhibition Hall today, March ...
... With Needle-free Vaccine Technology and ... Bird Flu Clinical Program, Webcast/teleconference ... IRVING, Texas, March 31 Carrington,Laboratories, Inc. (OTC Bulletin Board: CARN) ... million, or ($0.90) per basic and,diluted share, for the year ended ...
... MONMOUTH JUNCTION, N.J., March 31 Transave, ... inhaled,pharmaceuticals for the site-specific treatment of serious ... an aggregate of $35 million pursuant to,its ... Company,s,Board are Richard Kollender from Quaker BioVentures ...
Cached Biology Technology:NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update 2NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update 3Carrington Reports 2007 Financial Results 2Carrington Reports 2007 Financial Results 3Carrington Reports 2007 Financial Results 4Carrington Reports 2007 Financial Results 5Carrington Reports 2007 Financial Results 6Carrington Reports 2007 Financial Results 7Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing 2Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing 3
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a market ... appointed Steve Gerber to the new role of ... responsible for leading development of mobile platforms and wearable solutions ... success and innovation in the semiconductor industry to his role ...
(Date:12/22/2014)... 2014 Holiday Season may be the brightest ever for ... the long anticipated floodgates for consumer biometrics may finally ... phones, tablets, and wearable mobile devices that incorporate biometrics ... with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 Based ... 5S, Samsung introduces for the first time a fingerprint ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... entomologists will meet June 16-19, 2013 at the Best Western ... South Dakota as the Entomological Society of America,s North Central ... will include: , Forests pests, such as the ... Agricultural insect pests such as the western corn rootworm, the ...
... Paris, France: The group of genetic conditions known as ... always fatal, in the case of affected children at an ... gait, and poor co-ordination of hands, speech and eye movements, ... researchers from France and the US have found a new ...
... (June 9, 2013) Researchers at Whitehead Institute have ... the drugs that are used to increase red blood ... including those resulting from trauma, sepsis, malaria, kidney dialysis, ... capable of increasing this protein,s production without causing the ...
Cached Biology News:Interferon-beta aids balance and movement in mice with spinocerebellar ataxia 7 2Interferon-beta aids balance and movement in mice with spinocerebellar ataxia 7 3Scientists identify potential drug target for treatment-resistant anemias 2
... Wash Pack provides optimized blocking and ... Quality Clarifier: Ready-to-use wash solutions have ... APS Coated Slides for Microarrays (Product ... Blocking Buffer: 1L • Microarray Post ...
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
Mouse monoclonal antibody raised against a partial recombinant NEK2. NCBI Entrez Gene ID = NEK2...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
Biology Products: